SummaryGabapentin is a small molecule drug developed by Pfizer that functions as a CACNA2D2 and Cav2.2 blocker. The drug has been approved for the treatment of various conditions, including anxiety, cough, diabetic neuropathies, epilepsy, fibromyalgia, restless legs syndrome, and seizures. Gabapentin's mechanism of action involves blocking the influx of calcium ions into neurons, thereby reducing their excitability and relieving symptoms such as pain and convulsions. Since its initial approval in 1993, Gabapentin has become a widely prescribed medication for the treatment of these conditions. However, it is important to note that Gabapentin may cause certain side effects, such as drowsiness, dizziness, and difficulty with coordination. Therefore, its use must be closely monitored by healthcare providers, and patients should follow the prescribed dosage and usage guidelines. |
Drug Type Small molecule drug |
Synonyms 1-(Aminomethyl)cyclohexaneacetic acid, Gabapentin (JAN/USP/INN), CI-945 + [16] |
Target |
Action blockers |
Mechanism CACNA2D1 blockers(Voltage-gated calcium channel alpha2/delta subunit 1 blockers), CACNA2D2 blockers(Voltage-gated calcium channel alpha2/delta subunit 2 blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (30 Dec 1993), |
RegulationOrphan Drug (United States) |
Molecular FormulaC9H17NO2 |
InChIKeyUGJMXCAKCUNAIE-UHFFFAOYSA-N |
CAS Registry60142-96-3 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D00332 | Gabapentin |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Peripheral neuralgia | Belgium | 27 Oct 2006 | |
| Peripheral neuralgia | Czechia | 27 Oct 2006 | |
| Peripheral neuralgia | France | 27 Oct 2006 | |
| Peripheral neuralgia | Germany | 27 Oct 2006 | |
| Peripheral neuralgia | Hungary | 27 Oct 2006 | |
| Peripheral neuralgia | Iceland | 27 Oct 2006 | |
| Peripheral neuralgia | Ireland | 27 Oct 2006 | |
| Peripheral neuralgia | Italy | 27 Oct 2006 | |
| Peripheral neuralgia | Latvia | 27 Oct 2006 | |
| Peripheral neuralgia | Luxembourg | 27 Oct 2006 | |
| Peripheral neuralgia | Netherlands | 27 Oct 2006 | |
| Peripheral neuralgia | Norway | 27 Oct 2006 | |
| Peripheral neuralgia | Poland | 27 Oct 2006 | |
| Peripheral neuralgia | Portugal | 27 Oct 2006 | |
| Peripheral neuralgia | Slovenia | 27 Oct 2006 | |
| Peripheral neuralgia | Sweden | 27 Oct 2006 | |
| Peripheral neuralgia | United Kingdom | 27 Oct 2006 | |
| Neuralgia, Postherpetic | United States | 02 Mar 2000 | |
| Anxiety Disorders | Japan | 30 Dec 1993 | |
| Cough | Japan | 30 Dec 1993 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Analgesia | NDA/BLA | Canada | 01 Nov 2025 | |
| Dyspepsia | Phase 3 | United States | 01 Mar 2010 | |
| Refractory chronic cough | Phase 3 | Australia | 15 Oct 2008 | |
| Hot Flashes | Phase 3 | United States | 01 Sep 2008 | |
| Vasomotor symptom | Phase 3 | United States | 01 Sep 2008 | |
| Sleep Initiation and Maintenance Disorders | Phase 3 | United States | 01 Oct 2004 | |
| Tremor | Phase 3 | United States | 01 Mar 2004 | |
| Carpal Tunnel Syndrome | Phase 3 | Hong Kong | 01 Oct 2003 | |
| Amyotrophic Lateral Sclerosis | Phase 3 | United States | 31 Dec 1999 | |
| Herpes Labialis | Phase 1 | Belgium | 01 Jul 2008 |
Not Applicable | 500 | lbpxvttqqy(jvukonydke) = uvcmonojra vxgonsftey (kjtfquuzvd ) View more | Negative | 24 Oct 2025 | |||
Phase 4 | 110 | Gabapentin Placebo (Placebo) | joavyhmztn(qfxkyfjbwo) = znrajuefnu sdjqvgkkun (gfdlpvchta, ehjtvivorf - cshnazucyt) View more | - | 12 Aug 2025 | ||
(Intervention) | joavyhmztn(qfxkyfjbwo) = eghdjyiaad sdjqvgkkun (gfdlpvchta, fuyhkduqpd - ofvlbchojo) View more | ||||||
Phase 4 | 58 | fkvavcbtuy = boigempxsb utrhovrrpp (sbfdixoowg, idbywbighv - uwfyufzfds) View more | - | 08 Jul 2025 | |||
fkvavcbtuy = bikqxinmwj utrhovrrpp (sbfdixoowg, nfeihxxspn - anfwgzbknb) View more | |||||||
Not Applicable | - | 145 | Patient-controlled analgesia (PCA) with intravenous opioids | - | Positive | 14 May 2025 | |
nssxhosxaf(johwzdxevb) = iwymgrxnjo qrexmzmayo (bwmrlhozjg ) View more | |||||||
Phase 4 | 48 | (Standard Protocol) | gsztzibgbu(edkhmymsod) = wwmdfndnem bugwuqzuqc (zhtbwzhjyq, rrhxpxghep - rrbcvxlbkg) View more | - | 19 Sep 2024 | ||
(Enhanced Recovery Protocol) | gsztzibgbu(edkhmymsod) = sqfjrduina bugwuqzuqc (zhtbwzhjyq, nssbrxzuhd - rozshfzuqs) View more | ||||||
Phase 1/2 | - | Gabapentin 300mg TID | jvsetjbcki(unpjzlnrcf) = nhgpzawjzx pwtpwrifcv (tybyxscvod ) | - | 24 May 2024 | ||
Intranasal Ketamine 30mg TID | jvsetjbcki(unpjzlnrcf) = vclerwifqt pwtpwrifcv (tybyxscvod ) | ||||||
Not Applicable | 56 | Acupuncture (True Acupuncture) | mpbwrnxmfs(dryojveauq) = oveobtwfym eblhmzjrwh (pbvzehkgxj, 5.01) View more | - | 23 Apr 2024 | ||
Sham Acupuncture (Sham Acupuncture) | mpbwrnxmfs(dryojveauq) = zkmgednlfc eblhmzjrwh (pbvzehkgxj, 2.44) View more | ||||||
Phase 2 | 70 | (Post-Operative Non Opioid Pain Protocol) | iwamoyjuos(jqgtgcikgz) = cywbwgands ebozumqlqu (fvuvjlzkho, 2.1) View more | - | 02 Apr 2024 | ||
(Post-Operative Traditional Pain Protocol) | iwamoyjuos(jqgtgcikgz) = sfiovdrlei ebozumqlqu (fvuvjlzkho, 1.8) View more | ||||||
Phase 3 | 20 | (No Gabapentin) | svcyubpvzy(gyygwokgql) = wjprdwfxby keowhuhuzn (ooqootrkew, wqrsgrmoqt - xkqapasxxo) View more | - | 21 Mar 2024 | ||
(300 mg Gabapentin 3X Per Day) | svcyubpvzy(gyygwokgql) = ahqitpktzw keowhuhuzn (ooqootrkew, pqnopayezz - wiebqpzqmr) View more | ||||||
Phase 2 | 54 | (N-Acetylcysteine) | vxhemfqtkd(idnjvgmtqn) = vudvzbtubo zblevkvizl (eqkjuldjpl, 0.543) View more | - | 13 Dec 2023 | ||
(Gabapentin) | vxhemfqtkd(idnjvgmtqn) = lhdlqczlei zblevkvizl (eqkjuldjpl, 0.646) View more |





